Source: PRNews/Tisch MS Research Center / Photo: Scientist from Tisch MSRCNY preparing stem cells for injection into a patient with MS
(NEW YORK, NY) — Tisch MS Research Center of New York (Tisch MSRCNY) today announced encouraging preliminary results from its FDA-approved Phase I trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic autoimmune disease of the central nervous system where the myelin sheath is attacked and neurodegeneration may occur. It affects more than 2.3 million people worldwide. The significant results were selected for presentation during theMultiple Sclerosis Highlights in the Field session at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Tisch MSRCNY research showed that in the interim analysis, six of nine patients are exhibiting increased motor strength, improved bladder function and an enhanced quality of life. Importantly, the treatments are well tolerated and thus far no serious adverse events were reported.
“This preliminary data is encouraging because in addition to helping establish safety and tolerability, the trial is yielding some positive therapeutic results even at this early stage,” said Dr. Saud A. Sadiq, Chief Research Scientist at Tisch MSRCNY and the study’s principal investigator. He cautioned however, that these results are an interim analysis and definitive conclusions will only be made upon completion of the trial.
The study investigates a pioneering regenerative strategy using stem cells harvested from the patient’s own bone marrow. These stem cells are injected intrathecally (into the cerebrospinal fluid surrounding the spinal cord) in 20 participants who meet the inclusion criteria for the trial. The interim analysis reports on the first nine patients that have received at least one treatment of stem cells.